Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 14 November 2025 (earnings forecast); 15 May 2025 (dividend forecast)The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
In Japan, the company did not secure enough of the contracts it had targeted for the second half of the year, while in the US and Europe, the start of large-scale international joint clinical trials was delayed due to the shutdown of US government agencies and delays in preceding trials, among other factors.
| Item | Details |
|---|---|
| Net Sales | ¥9,350 million → ¥8,663 million（-7.3%） |
| Operating profit | ¥-1,350 million → ¥-2,138 million |
| Ordinary income | ¥-1,400 million → ¥-2,101 million |
| Profit attributable to owners of the parent | ¥-1,700 million → ¥-2,377 million |
| Net income per share | -75.27 yen → -105.24 yen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 14 November 2025 (earnings forecast); 15 May 2025 (dividend forecast) |
| Previous-period results | Fiscal year ended March 2025: net sales ¥10,437 million; operating loss ¥583 million; ordinary loss ¥498 million; net loss attributable to owners of the parent ¥539 million; net loss per share ¥23.87 |
| Reason for the revision | In Japan, the company did not secure enough of the contracts it had targeted for the second half of the year, while in the US and Europe, the start of large-scale international joint clinical trials was delayed due to the shutdown of US government agencies and delays in preceding trials, among other factors. |
| Dividend forecast revision | The year-end dividend has been reduced by ¥8.00, from ¥16.00 to ¥8.00, and the annual dividend has been revised from ¥16.00 to ¥8.00 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Japan, the company did not secure enough of the contracts it had targeted for the second half of the year. In the US and Europe, the start of most of the large-scale international joint clinical trials for which orders had been expected was delayed due to the shutdown of US government agencies and delays in preceding trials, among other factors. In response to the downward revision to the earnings forecast and the reduction in the dividend forecast, directors’ and other officers’ remuneration will be reduced to clarify management’s responsibility.